Merck to make new investments in Singapore

Merck has signed an agreement to expand its presence in Singapore through new manufacturing, marketing and research investments. 

Under the agreement with the Singapore Economic Development Board, Merck will invest more than $250 million over the next 10 years in site improvements at its manufacturing facilities in Tuas. It will also expand its biotech operations, adding capability to support new product launches. In addition, it will collaborate with local universities to help broaden the technical expertise of its local workforce.

Merck employs roughly 1,500 people in Singapore, where it established its manufacturing operations in 1996. The total value of Merck's investments in Singapore thus far are roughly $1.5 billion.

Merck isn't the only company eyeing Singapore. Over the past few months, Lonza has announced a $12 million plan to expand its biopharmaceutical development services platform there and plans a secondary listing on the Singapore Stock Exchange.

- see the Merck release

Suggested Articles

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.